JPWO2022148979A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022148979A5 JPWO2022148979A5 JP2023541750A JP2023541750A JPWO2022148979A5 JP WO2022148979 A5 JPWO2022148979 A5 JP WO2022148979A5 JP 2023541750 A JP2023541750 A JP 2023541750A JP 2023541750 A JP2023541750 A JP 2023541750A JP WO2022148979 A5 JPWO2022148979 A5 JP WO2022148979A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- harg
- referred
- iii
- hyp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 194
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 122
- 239000008194 pharmaceutical composition Substances 0.000 claims description 97
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 93
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims description 76
- 239000003446 ligand Substances 0.000 claims description 54
- 125000002619 bicyclic group Chemical group 0.000 claims description 51
- 150000003839 salts Chemical class 0.000 claims description 50
- 206010028980 Neoplasm Diseases 0.000 claims description 49
- 201000011510 cancer Diseases 0.000 claims description 42
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 21
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 21
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 19
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 14
- 102100035486 Nectin-4 Human genes 0.000 claims description 13
- 101710043865 Nectin-4 Proteins 0.000 claims description 13
- 239000002955 immunomodulating agent Substances 0.000 claims description 13
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims description 12
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims description 12
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical group NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 12
- MLBYLEUJXUBIJJ-UHFFFAOYSA-N pent-4-ynoic acid Chemical group OC(=O)CCC#C MLBYLEUJXUBIJJ-UHFFFAOYSA-N 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 238000011191 terminal modification Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 10
- 239000002062 molecular scaffold Substances 0.000 claims description 10
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 claims description 8
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 8
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 8
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 8
- PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 7
- 229960002885 histidine Drugs 0.000 claims description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 claims description 6
- -1 CEACAM-1 Proteins 0.000 claims description 6
- 150000001413 amino acids Chemical group 0.000 claims description 6
- 229940000635 beta-alanine Drugs 0.000 claims description 6
- 238000002619 cancer immunotherapy Methods 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 229960003151 mercaptamine Drugs 0.000 claims description 6
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical group C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 6
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical group OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 claims description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 4
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- 102000017578 LAG3 Human genes 0.000 claims description 4
- 101150030213 Lag3 gene Proteins 0.000 claims description 4
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical group C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 claims description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 229960003852 atezolizumab Drugs 0.000 claims description 3
- 229950009791 durvalumab Drugs 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 229960005386 ipilimumab Drugs 0.000 claims description 3
- 229960003301 nivolumab Drugs 0.000 claims description 3
- 229960002621 pembrolizumab Drugs 0.000 claims description 3
- WRQSUCJAKAMYMQ-YFKPBYRVSA-N (2s)-2-(thiophen-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC=1C=CSC=1 WRQSUCJAKAMYMQ-YFKPBYRVSA-N 0.000 claims description 2
- PECGVEGMRUZOML-AWEZNQCLSA-N (2s)-2-amino-3,3-diphenylpropanoic acid Chemical group C=1C=CC=CC=1C([C@H](N)C(O)=O)C1=CC=CC=C1 PECGVEGMRUZOML-AWEZNQCLSA-N 0.000 claims description 2
- WBZIGVCQRXJYQD-YFKPBYRVSA-N (2s)-2-amino-3-(1,3-thiazol-4-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CSC=N1 WBZIGVCQRXJYQD-YFKPBYRVSA-N 0.000 claims description 2
- SRGOJUDAJKUDAZ-LURJTMIESA-N (2s)-2-amino-3-cyclobutylpropanoic acid Chemical group OC(=O)[C@@H](N)CC1CCC1 SRGOJUDAJKUDAZ-LURJTMIESA-N 0.000 claims description 2
- JPSHPWJJSVEEAX-OWPBQMJCSA-N (2s)-2-amino-4-fluoranylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC([18F])C(O)=O JPSHPWJJSVEEAX-OWPBQMJCSA-N 0.000 claims description 2
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 claims description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 claims description 2
- 102100031934 Adhesion G-protein coupled receptor G1 Human genes 0.000 claims description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 2
- 102100036008 CD48 antigen Human genes 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 claims description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
- 108010001498 Galectin 1 Proteins 0.000 claims description 2
- 102100031351 Galectin-9 Human genes 0.000 claims description 2
- 101710121810 Galectin-9 Proteins 0.000 claims description 2
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 claims description 2
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims description 2
- 101000775042 Homo sapiens Adhesion G-protein coupled receptor G1 Proteins 0.000 claims description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 2
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims description 2
- 101001023712 Homo sapiens Nectin-3 Proteins 0.000 claims description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 2
- OYIFNHCXNCRBQI-BYPYZUCNSA-N L-2-aminoadipic acid Chemical compound OC(=O)[C@@H](N)CCCC(O)=O OYIFNHCXNCRBQI-BYPYZUCNSA-N 0.000 claims description 2
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 claims description 2
- BRMWTNUJHUMWMS-LURJTMIESA-N N(tele)-methyl-L-histidine Chemical compound CN1C=NC(C[C@H](N)C(O)=O)=C1 BRMWTNUJHUMWMS-LURJTMIESA-N 0.000 claims description 2
- 102100035487 Nectin-3 Human genes 0.000 claims description 2
- 229940124060 PD-1 antagonist Drugs 0.000 claims description 2
- 235000021314 Palmitic acid Nutrition 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 claims description 2
- 101710174757 T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 claims description 2
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 claims description 2
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 claims description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 claims description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102100021736 Galectin-1 Human genes 0.000 claims 1
- 238000009175 antibody therapy Methods 0.000 claims 1
- 238000001815 biotherapy Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- FYBFGAFWCBMEDG-UHFFFAOYSA-N 1-[3,5-di(prop-2-enoyl)-1,3,5-triazinan-1-yl]prop-2-en-1-one Chemical compound C=CC(=O)N1CN(C(=O)C=C)CN(C(=O)C=C)C1 FYBFGAFWCBMEDG-UHFFFAOYSA-N 0.000 description 1
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 102000000795 Galectin 1 Human genes 0.000 description 1
- 101150046249 Havcr2 gene Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 1
- 102100034980 ICOS ligand Human genes 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 101100369641 Mus musculus Tigit gene Proteins 0.000 description 1
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000004473 OX40 Ligand Human genes 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 description 1
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135865P | 2021-01-11 | 2021-01-11 | |
| US202163135858P | 2021-01-11 | 2021-01-11 | |
| US63/135,865 | 2021-01-11 | ||
| US63/135,858 | 2021-01-11 | ||
| US202163138019P | 2021-01-15 | 2021-01-15 | |
| US63/138,019 | 2021-01-15 | ||
| PCT/GB2022/050055 WO2022148979A1 (en) | 2021-01-11 | 2022-01-11 | Methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024502189A JP2024502189A (ja) | 2024-01-17 |
| JPWO2022148979A5 true JPWO2022148979A5 (enrdf_load_stackoverflow) | 2025-01-21 |
Family
ID=80446048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541750A Pending JP2024502189A (ja) | 2021-01-11 | 2022-01-11 | 癌を処置する方法 |
Country Status (10)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107148425B (zh) | 2014-10-29 | 2021-08-03 | 拜斯科阿迪有限公司 | 对mt1-mmp特异性的双环肽配体 |
| ES2926195T3 (es) | 2017-08-04 | 2022-10-24 | Bicycletx Ltd | Ligandos peptídicos bicíclicos específicos de CD137 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| US10875894B2 (en) | 2018-02-23 | 2020-12-29 | Bicycletx Limited | Multimeric bicyclic peptide ligands |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| TWI862640B (zh) | 2019-07-30 | 2024-11-21 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| WO2024229427A1 (en) * | 2023-05-04 | 2024-11-07 | Tambo, Inc. | Tetrazine-based targeting agents for in vivo delivery of a payload |
| WO2025125652A1 (en) | 2023-12-13 | 2025-06-19 | Bicycletx Limited | Combination therapy for use in treating cancer |
| WO2025125648A1 (en) * | 2023-12-13 | 2025-06-19 | Bicycletx Limited | Bicyclic peptide complex for use in treating cancer |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| NZ560504A (en) | 2005-01-24 | 2009-07-31 | Pepscan Systems Bv | Binding compounds, immunogenic compounds and peptidomimetics |
| ES2657443T3 (es) | 2005-03-25 | 2018-03-05 | Gitr, Inc. | Anticuerpos anti-GITR y usos de los mismos |
| SG163554A1 (en) | 2005-07-01 | 2010-08-30 | Medarex Inc | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| WO2009009116A2 (en) | 2007-07-12 | 2009-01-15 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ｉｄｏ阻害剤 |
| DK2474613T3 (da) | 2008-02-05 | 2014-10-06 | Bicycle Therapeutics Ltd | Fremgangsmåder og sammensætninger |
| WO2009156652A1 (fr) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Structure en nid d'abeille a base de titanate d'aluminium |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MY188826A (en) | 2008-12-09 | 2022-01-06 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| MX340953B (es) | 2009-09-03 | 2016-07-29 | Merck Sharp & Dohme Corp * | Anticuerpos anti receptor del factor de necrosis tumoral inducido por glucocorticoides. |
| PE20121398A1 (es) | 2009-12-10 | 2012-10-26 | Hoffmann La Roche | Anticuerpos ligantes preferentemente al dominio extracelular 4 de csf1r humano |
| BR112012022046A2 (pt) | 2010-03-05 | 2017-02-14 | F Hoffamann-La Roche Ag | ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''. |
| KR101656548B1 (ko) | 2010-03-05 | 2016-09-09 | 에프. 호프만-라 로슈 아게 | 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도 |
| MX2012012790A (es) | 2010-05-04 | 2013-02-15 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| PL2614082T3 (pl) | 2010-09-09 | 2019-02-28 | Pfizer Inc. | Cząsteczki wiążące 4-1BB |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| NO2694640T3 (enrdf_load_stackoverflow) | 2011-04-15 | 2018-03-17 | ||
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| SG11201402603WA (en) | 2011-11-28 | 2014-06-27 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| JP6416630B2 (ja) | 2012-02-06 | 2018-10-31 | ジェネンテック， インコーポレイテッド | Ｃｓｆ１ｒ阻害剤を用いるための組成物及び方法 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| CA2871445C (en) | 2012-05-11 | 2020-07-07 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| EP3679949A1 (en) | 2012-08-31 | 2020-07-15 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| CN107148425B (zh) | 2014-10-29 | 2021-08-03 | 拜斯科阿迪有限公司 | 对mt1-mmp特异性的双环肽配体 |
| GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| CA3046156A1 (en) | 2016-12-23 | 2018-06-28 | Bicycletx Limited | Peptide ligands for binding to mt1-mmp |
| ES2926195T3 (es) | 2017-08-04 | 2022-10-24 | Bicycletx Ltd | Ligandos peptídicos bicíclicos específicos de CD137 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| WO2019193328A1 (en) | 2018-04-04 | 2019-10-10 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
| GB201810325D0 (en) | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to PSMA |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| EP3897849A1 (en) | 2018-12-21 | 2021-10-27 | BicycleTx Limited | Bicyclic peptide ligands specific for pd-l1 |
| CN113260420A (zh) | 2018-12-21 | 2021-08-13 | 拜斯科阿迪有限公司 | Pd-l1特异性的双环肽配体 |
| TWI862640B (zh) * | 2019-07-30 | 2024-11-21 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| US20220275053A1 (en) * | 2019-08-13 | 2022-09-01 | Bicycletx Limited | Modified multimeric bicyclic peptide ligands |
| CN119192401A (zh) * | 2019-10-03 | 2024-12-27 | 拜斯科技术开发有限公司 | 异串联双环肽复合物 |
| EP4196792A1 (en) * | 2020-08-17 | 2023-06-21 | BicycleTX Limited | Bicycle conjugates specific for nectin-4 and uses thereof |
-
2022
- 2022-01-10 US US18/271,593 patent/US20250186539A2/en active Pending
- 2022-01-11 WO PCT/GB2022/050055 patent/WO2022148979A1/en active Application Filing
- 2022-01-11 KR KR1020237027291A patent/KR20230146528A/ko active Pending
- 2022-01-11 EP EP22705559.7A patent/EP4274597A1/en active Pending
- 2022-01-11 AU AU2022206395A patent/AU2022206395A1/en active Pending
- 2022-01-11 JP JP2023541750A patent/JP2024502189A/ja active Pending
- 2022-01-11 MX MX2023008193A patent/MX2023008193A/es unknown
- 2022-01-11 TW TW111101177A patent/TW202241488A/zh unknown
- 2022-01-11 CA CA3204630A patent/CA3204630A1/en active Pending
-
2023
- 2023-07-05 IL IL304275A patent/IL304275A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240325554A1 (en) | Methods for treating cancer | |
| JP7296958B2 (ja) | 手術前、手術中または手術後に投与するためのｇｌｐ－２類似体及びｇｌｐ－２ペプチボディ | |
| WO2015044900A1 (en) | Therapeutic immunomodulating compounds | |
| WO2016164428A1 (en) | Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway | |
| CN119097699A (zh) | B7-h4抗体及其使用方法 | |
| TW202309073A (zh) | IL2R βγc結合化合物及其用途 | |
| TWI820361B (zh) | 包含含有il-2蛋白與cd80蛋白之融合蛋白及免疫檢查點抑制劑的用於治療癌症的藥學組成物 | |
| JPWO2022148979A5 (enrdf_load_stackoverflow) | ||
| US20230331858A1 (en) | Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor | |
| CN113543809A (zh) | 用于治疗癌症的免疫疗法 | |
| IL301454A (en) | Clinical dosing of sirp1a chimeric protein | |
| JPWO2020225577A5 (enrdf_load_stackoverflow) | ||
| EP4430086A1 (en) | Sirp1a - and cd40l-based chimeric proteins | |
| CN117603355A (zh) | 结合pd-1的抗体 | |
| TW201938580A (zh) | Ｈｍｇｎ部分肽及使用其之癌症療法 | |
| CN119183381A (zh) | 增强免疫检查点抑制剂治疗的方法 | |
| KR20230056761A (ko) | Pd-1 저해제의 투여에 의한 암 치료 방법 | |
| WO2019204402A1 (en) | Compositions and methods for treatment of cancer | |
| HK40074839A (en) | Pharmaceutical composition for treatment of cancer, comprising immune checkpoint inhibitor and fusion protein including il-2 protein and cd80 protein | |
| WO2024173352A2 (en) | Methods of treating cancer with a sirp1a-based chimeric protein | |
| WO2025125652A1 (en) | Combination therapy for use in treating cancer | |
| KR20200039755A (ko) | 암 치료를 위한 치료학적 조합 및 방법 | |
| JPWO2021089588A5 (enrdf_load_stackoverflow) |